Abstract

AbstractDimethylcurcumin (ASC−J9, DMC), a newly developed anti‐AR agent, suppresses androgen receptor (AR) signaling pathways by degradation of full‐length and splice variant of ARs, showing efficient growth inhibition effect on castration‐resistant prostate cancer (PCa). However, DMC is extremely hydrophobic, which significantly limits its applications. Here, we developed DMC‐loaded methoxylpoly (ethylene glycol)‐retinoic acid (DMC@mPEG2000‐RA) micelles in order to improve the solubility of DMC and its effect on growth inhibition of castration‐resistant PCa. DMC@mPEG2000‐RA micelles with hydrodynamic diameter around 200 nm and drug loading content of 6.0% were prepared by thin film hydration‐ultrasonic method. The as prepared micelles show good colloidal stability in PBS buffer and 10% FBS containing PBS buffer. The in vitro drug release study shows that DMC@mPEG2000‐RA micelles exhibit initially relative fast drug release followed by sustained drug release behaviors. The cellular uptake study reveals that the cellular uptake amount of DMC@mPEG2000‐RA micelles is significantly higher than that of free DMC and caveolae plays important roles in cellular uptake of DMC@mPEG2000‐RA micelles. Finally, DMC@mPEG2000‐RA micelles exhibit significantly enhanced in vitro antitumor activity against C4‐2 and 22Rv1 cells as compared to free DMC. DMC@mPEG2000‐RA micelles were proved to be an efficient formulation of DMC for suppression of castration‐resistant PCa.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.